MedTech Europe has issued a statement calling on European policymakers to exempt medical technologies from any trade tariffs or export restrictions.
In response to the European Commission’s (EC) conclusion of a public consultation on proposed EU countermeasures impacting trade with the US, MedTech Europe expressed deep concern over a draft package that “targets a broad range of finished medical devices, in vitro diagnostic (IVD) medical devices, and a variety of essential components used in their manufacture”.
The trade body’s overall request was that medical technologies be included and prioritised in a “zero for zero” tariff agreement on industrial goods or as part of any negotiated settlement that seeks to eliminate tariffs on both sides of the Atlantic.
The EC’s consultation, which was announced on 8 May and closed on 10 June, was launched to gather input towards finalising proposals for the adoption of countermeasures against the Trump’s administration’s imposition of tariffs on the bloc.
Upon launching the consultation, EC president Ursula von der Leyen said: “Tariffs are already having a negative impact on the global economies. The EU remains fully committed to finding negotiated outcomes with the US.
“At the same time, we continue preparing for all possibilities, and the consultation launched today will help guide us in this necessary work.”
President Trump’s initial announcement of tariffs for many countries and regions worldwide on 2 April has been marked by continued flip-flopping. The EU was originally facing 20% blanket tariffs on all imported goods from 9 April; however, the White House walked back its plans on the date, instead choosing to enact a 90-day pause on the imposition of tariffs.
Trump has since threatened to raise tariffs on the EU to 50% if no deal is reached by the end of the pause period on 9 July.
According to reports by German newspaper Handelsblatt, the EU was willing to accept a flat fee of 10% tariffs. However, in a statement shared with Reuters, the EC dismissed the claims, stating: “Negotiations are ongoing, and no agreement has been reached at this stage. The EU has from the start objected to unjustified and illegal US tariffs.”
In concluding remarks, MedTech Europe stated: “Patients must not become collateral damage in a trade dispute. Safeguarding their access to the technologies they depend on must remain a shared priority.”
On 11 June, leading players from the medtech industry convened on Capitol Hill alongside the Advanced Medical Technology Association (AdvaMed) to advocate for the elimination of tariffs on medical technologies.
After the Trump administration’s announcement of a 90-day pause on the imposition of tariffs for most countries, barring China, AdvaMed CEO Scott Whitaker voiced similar hopes as MedTech Europe, restating his previous request that a ‘zero for zero’ tariff deal on medtech with all of the US’s key trading partners be struck. GlobalData